-
1
-
-
0036014092
-
Plasmapheresis: Technical aspects and indications
-
Madore F. Plasmapheresis: technical aspects and indications. Crit Care Clin 2002 18 375 92.
-
(2002)
Crit Care Clin
, vol.18
, pp. 375-92
-
-
Madore, F.1
-
2
-
-
0038779507
-
Plasmapheresis in immune haematology: Review of clinical outcome data with respect to evidence-based medicine and clinical experience
-
Baeyer H. Plasmapheresis in immune haematology: review of clinical outcome data with respect to evidence-based medicine and clinical experience. Ther Apher Dial 2003 7 127 40.
-
(2003)
Ther Apher Dial
, vol.7
, pp. 127-40
-
-
Baeyer, H.1
-
3
-
-
0038646302
-
Indications of plasma exchange for systemic vasculitis
-
Guillevin L Pagnoux C. Indications of plasma exchange for systemic vasculitis. Ther Apher Dial 2003 7 155 60.
-
(2003)
Ther Apher Dial
, vol.7
, pp. 155-60
-
-
Guillevin, L.1
Pagnoux, C.2
-
4
-
-
12344286801
-
Plasmapheresis in neurological diseases: Experience in 140 procedures in 47 patients
-
Nogates-Gaete J Valenzuela D Liendo F et al. Plasmapheresis in neurological diseases: experience in 140 procedures in 47 patients. Rev Med Chil 2004 123 295 8.
-
(2004)
Rev Med Chil
, vol.123
, pp. 295-8
-
-
Nogates-Gaete, J.1
Valenzuela, D.2
Liendo, F.3
-
5
-
-
0019314538
-
Surface activation of blood coagulation, fibrinolysis and kinin formation
-
Heimark RL Kurachi RK Fujikawa K Davie EW. Surface activation of blood coagulation, fibrinolysis and kinin formation. Nature 1980 286 456 560.
-
(1980)
Nature
, vol.286
, pp. 456-560
-
-
Heimark, R.L.1
Kurachi, R.K.2
Fujikawa, K.3
Davie, E.W.4
-
6
-
-
0020445531
-
Use of heparin for cytapheresis and plasmapheresis in a continuous flow centrifuge
-
Morales M Pizzuto J Reyna MA et al. Use of heparin for cytapheresis and plasmapheresis in a continuous flow centrifuge. Transfusion 1982 22 384 7.
-
(1982)
Transfusion
, vol.22
, pp. 384-7
-
-
Morales, M.1
Pizzuto, J.2
Reyna, M.A.3
-
8
-
-
0024315960
-
Optimization of heparinization in clinical double filtration plasmapheresis
-
Hosokawa S Oyamaguchi A Yoshida O. Optimization of heparinization in clinical double filtration plasmapheresis. Int J Artif Organs 1989 12 544 8.
-
(1989)
Int J Artif Organs
, vol.12
, pp. 544-8
-
-
Hosokawa, S.1
Oyamaguchi, A.2
Yoshida, O.3
-
9
-
-
0024992853
-
Clinical studies on adequate dosage of heparin during immunoadorption with membrane plasmapheresis
-
Hosokawa S Oyamaguchi A Yoshida O. Clinical studies on adequate dosage of heparin during immunoadorption with membrane plasmapheresis. J Clin Apheresis 1990 5 197 200.
-
(1990)
J Clin Apheresis
, vol.5
, pp. 197-200
-
-
Hosokawa, S.1
Oyamaguchi, A.2
Yoshida, O.3
-
10
-
-
0025010826
-
Effect of anticoagulant on biocompatibility in membrane plasmapheresis
-
Omokawa S Malchesky PS Yamashita M et al. Effect of anticoagulant on biocompatibility in membrane plasmapheresis. Int J Artif Organs 1990 13 768 77.
-
(1990)
Int J Artif Organs
, vol.13
, pp. 768-77
-
-
Omokawa, S.1
Malchesky, P.S.2
Yamashita, M.3
-
11
-
-
0037560252
-
Influence of different heparin concentrations on the results of in vitro investigations in plasmaseperation technology using capillary membrane filters
-
Unger KU Haltern C Dohmen B Rossaint R. Influence of different heparin concentrations on the results of in vitro investigations in plasmaseperation technology using capillary membrane filters. Artif Organs 2003 27 649 57.
-
(2003)
Artif Organs
, vol.27
, pp. 649-57
-
-
Unger, K.U.1
Haltern, C.2
Dohmen, B.3
Rossaint, R.4
-
12
-
-
0034046318
-
The effect of plasmapheresis on the serum activity level of dalteparin: A case report
-
Sabloff M Wells PS. The effect of plasmapheresis on the serum activity level of dalteparin: a case report. Blood Coagul Fibrinolysis 2000 11 395 400.
-
(2000)
Blood Coagul Fibrinolysis
, vol.11
, pp. 395-400
-
-
Sabloff, M.1
Wells, P.S.2
-
13
-
-
0023828836
-
Determination of human thrombin- antithrombin III-complex in plasma with an enzym-linked immunosorbent assay
-
Pelzer H Schwarz A Heimburger N. Determination of human thrombin- antithrombin III-complex in plasma with an enzym-linked immunosorbent assay. Thromb Haemost 1988 59 101 6.
-
(1988)
Thromb Haemost
, vol.59
, pp. 101-6
-
-
Pelzer, H.1
Schwarz, A.2
Heimburger, N.3
-
14
-
-
0026071629
-
Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide
-
Pelzer H Schwarz A Stüber W. Determination of human prothrombin activation fragment 1+2 in plasma with an antibody against a synthetic peptide. Thromb Haemost 1991 65 153 9.
-
(1991)
Thromb Haemost
, vol.65
, pp. 153-9
-
-
Pelzer, H.1
Schwarz, A.2
Stüber, W.3
-
15
-
-
0020085770
-
Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2-fragment and thrombin-antithrombin-complex
-
Teiel JM Bauer KA Lau HK Rosenberg RD. Studies of the prothrombin activation pathway utilizing radioimmunoassays for the F2/F1+2-fragment and thrombin-antithrombin-complex. Blood 1982 59 1086 97.
-
(1982)
Blood
, vol.59
, pp. 1086-97
-
-
Teiel, J.M.1
Bauer, K.A.2
Lau, H.K.3
Rosenberg, R.D.4
-
16
-
-
0026758761
-
Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination
-
Bruhn HD Conard J Manucci M et al. Multicentric evaluation of a new assay for prothrombin fragment 1+2 determination. Thromb Haemost 1992 68 413 7.
-
(1992)
Thromb Haemost
, vol.68
, pp. 413-7
-
-
Bruhn, H.D.1
Conard, J.2
Manucci, M.3
-
17
-
-
26444493740
-
A simple chromogenic assay for heparin and heparin-linked anti-F Xa acitivity in plasma
-
Holmer E et al. A simple chromogenic assay for heparin and heparin-linked anti-F Xa acitivity in plasma. Thromb Haemost 1985 53 278 81.
-
(1985)
Thromb Haemost
, vol.53
, pp. 278-81
-
-
Holmer, E.1
-
18
-
-
0023787586
-
An international standard for low molecular weight heparin
-
Barrowcliffe TW. An international standard for low molecular weight heparin. Thromb Haemost 1988 60 1 7.
-
(1988)
Thromb Haemost
, vol.60
, pp. 1-7
-
-
Barrowcliffe, T.W.1
-
19
-
-
7144260080
-
Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure
-
Anastassiades EG Lane DA Lynn A Curtis JR. Preliminary evaluation of repeated use of a low molecular weight heparin in hemodialysis for chronic renal failure. Proc Eur Dial Trans Assoc 1985 22 329 33.
-
(1985)
Proc Eur Dial Trans Assoc
, vol.22
, pp. 329-33
-
-
Anastassiades, E.G.1
Lane, D.A.2
Lynn, A.3
Curtis, J.R.4
-
20
-
-
0022857695
-
Hemodialysis with low molecular weight heparin: Dosage requirement for the elimination of extracorporeal fibrin formation
-
Lane DA Ireland H Flynn A Anastassiades E Curtis JR. Hemodialysis with low molecular weight heparin: dosage requirement for the elimination of extracorporeal fibrin formation. Nephrol Dial Transplant 1986 1 179 35.
-
(1986)
Nephrol Dial Transplant
, vol.1
, pp. 179-35
-
-
Lane, D.A.1
Ireland, H.2
Flynn, A.3
Anastassiades, E.4
Curtis, J.R.5
-
21
-
-
0023114607
-
A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis
-
Ljunberg B Blombäck M Johnsson H Lins LE. A single dose of a low molecular weight heparin fragment for anticoagulation during hemodialysis. Clin Nephrol 1987 27 31 5.
-
(1987)
Clin Nephrol
, vol.27
, pp. 31-5
-
-
Ljunberg, B.1
Blombäck, M.2
Johnsson, H.3
Lins, L.E.4
-
22
-
-
0025971904
-
Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®)
-
Swars H Hafner G Weilemann LS et al. Acute dialysis: PMN-elastase as a new parameter for controlling individual anticoagulation with low molecular weight heparin (Fragmin®). Intens Care Med 1991 17 52 6.
-
(1991)
Intens Care Med
, vol.17
, pp. 52-6
-
-
Swars, H.1
Hafner, G.2
Weilemann, L.S.3
-
23
-
-
0025203322
-
Clinical application of Fragmin (FR-860) in hemodialysis: Multicenter cooperative study in Japan
-
Suzuki T Ota K Naganuma S et al. Clinical application of Fragmin (FR-860) in hemodialysis: multicenter cooperative study in Japan. Semin Thromb Hemost 1990 16 46 54.
-
(1990)
Semin Thromb Hemost
, vol.16
, pp. 46-54
-
-
Suzuki, T.1
Ota, K.2
Naganuma, S.3
-
24
-
-
0032794346
-
A single dose of dalteparin effectively prevent clotting during haemodialysis: Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
-
Sagedal S Hartmann A Sundstrom K et al. A single dose of dalteparin effectively prevent clotting during haemodialysis: anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 1999 14 1943 7.
-
(1999)
Nephrol Dial Transplant
, vol.14
, pp. 1943-7
-
-
Sagedal, S.1
Hartmann, A.2
Sundstrom, K.3
-
25
-
-
0035025371
-
Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets
-
Sagedal S Hartmann A Sundstrom K Bjornsen S Brosstad F. Anticoagulation intensity sufficient for haemodialysis does not prevent activation of coagulation and platelets. Nephrol Dial Transplant 2001 16 987 93.
-
(2001)
Nephrol Dial Transplant
, vol.16
, pp. 987-93
-
-
Sagedal, S.1
Hartmann, A.2
Sundstrom, K.3
Bjornsen, S.4
Brosstad, F.5
-
27
-
-
0031680310
-
College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: The clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban
-
Laptosa M Green K Elizabeth MV et al. College of American Pathologists Conference XXXI on Laboratory Monitorin of Anticoagulant Therapy: the clinical use and laboratory monitoring of low-molecular-weight heparin, danaparoid, hirudin and related compounds, and argatroban. Arch Pathol Lab Med 1998 122 799 807.
-
(1998)
Arch Pathol Lab Med
, vol.122
, pp. 799-807
-
-
Laptosa, M.1
Green, K.2
Elizabeth, M.V.3
-
28
-
-
3242734130
-
Is laboratory monitoring of low-molecular-weight heaprin therapy necessary? Yes
-
Harenberg J. Is laboratory monitoring of low-molecular-weight heaprin therapy necessary? Yes. J Thromb Haemost 2004 2 547 50.
-
(2004)
J Thromb Haemost
, vol.2
, pp. 547-50
-
-
Harenberg, J.1
-
29
-
-
0025996472
-
Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin
-
Nieuwenhuis HK Albada J Banga JD et al. Identification of risk factors for bleeding during treatment of acute venous thromboembolism with heparin or low molecular weight heparin. Blood 1991 78 2337 43.
-
(1991)
Blood
, vol.78
, pp. 2337-43
-
-
Nieuwenhuis, H.K.1
Albada, J.2
Banga, J.D.3
|